Ascorbic Acid Deficiency Prevalence and Associated Cognitive Impairment in Alcohol Detoxification Inpatients: A Pilot Study.

HIV alcohol use disorder ascorbic acid central nervous system cognitive impairment homeless persons liver cirrhosis malnutrition sedative use disorder

Journal

Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981

Informations de publication

Date de publication:
26 Nov 2021
Historique:
received: 25 10 2021
revised: 23 11 2021
accepted: 24 11 2021
entrez: 24 12 2021
pubmed: 25 12 2021
medline: 25 12 2021
Statut: epublish

Résumé

Malnutrition has been reported in alcohol use disorder patients as having a possible influence on cognitive function. The aim of this study was to analyse the prevalence of ascorbic acid (AA) deficiency in inpatients admitted for alcohol detoxification and the associated factors, including cognitive impairment in the early period of abstinence. A retrospective chart review was conducted. The AA level was categorised into three groups: deficiency (AAD) (<2 mg/L), insufficiency (AAI) (2-5 mg/L) and normal level. The cognitive impairment was screened using the Montreal Cognitive Assessment (MoCA). Ninety-six patients were included (74 men; mean age 49.1 years (±11.5)). Twenty-seven AAD (28.1%) and twenty-two AAI (22.9%) were observed. In multivariate analysis, risk factors for AAD versus normal AA level were men (OR 17.8, 95%CI (1.63-194)), compensated cirrhosis (OR 9.35, 95%CI (1.60-54.6)) and street homelessness (OR 5.76, 95%CI (1.24-26.8) versus personal housing). The MoCA score was available for 53 patients (mean MoCA score: 25.7 (±3.3)). In multivariate analysis, the natural logarithm of AA (β = 1.18,

Identifiants

pubmed: 34942994
pii: antiox10121892
doi: 10.3390/antiox10121892
pmc: PMC8750659
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Glia. 2018 Jul;66(7):1302-1316
pubmed: 29423921
Addict Behav. 2020 Jun;105:106350
pubmed: 32070907
Crit Care. 2019 May 10;23(1):165
pubmed: 31077227
Clin Infect Dis. 2011 Oct;53(8):836-42
pubmed: 21921226
Rev Med Interne. 2004 Dec;25(12):872-80
pubmed: 15582167
J Public Health (Oxf). 2008 Dec;30(4):456-60
pubmed: 18812436
Am J Clin Nutr. 1994 Aug;60(2):255-61
pubmed: 8030604
Nutrients. 2013 Dec 16;5(12):5161-92
pubmed: 24352093
Eur J Intern Med. 2003 Nov;14(7):419-425
pubmed: 14614974
Am J Gastroenterol. 1998 Apr;93(4):665-6
pubmed: 9576477
Nutr Neurosci. 2021 Jul;24(7):530-541
pubmed: 31419185
Nutrients. 2019 Oct 09;11(10):
pubmed: 31601028
Nutrition. 2012 Jul;28(7-8):738-43
pubmed: 22356728
CMAJ. 2011 Aug 9;183(11):E752-5
pubmed: 21555388
Front Psychol. 2018 Dec 18;9:2618
pubmed: 30619013
Addiction. 2020 Aug;115(8):1580-1589
pubmed: 32112474
Eur J Clin Nutr. 2002 Apr;56(4):313-20
pubmed: 11965507
Alcohol Clin Exp Res. 2015 Jun;39(6):1042-8
pubmed: 25939560
Nutr Diet. 2020 Feb;77(1):76-89
pubmed: 31797519
Lancet Neurol. 2018 Nov;17(11):1006-1015
pubmed: 30244829
Am J Clin Nutr. 2009 Nov;90(5):1252-63
pubmed: 19675106
J Neurosci Res. 2013 Dec;91(12):1609-17
pubmed: 23996657
Nutrients. 2017 Aug 30;9(9):
pubmed: 28867798
J Am Coll Nutr. 1998 Aug;17(4):366-70
pubmed: 9710847
Gut. 1994 Nov;35(11):1637-43
pubmed: 7828989
J Korean Med Sci. 2015 Dec;30(12):1874-80
pubmed: 26713065
Intern Med J. 2019 Feb;49(2):189-196
pubmed: 29968401
J Clin Med Res. 2019 Jan;11(1):26-34
pubmed: 30627275
Int Immunopharmacol. 2018 Dec;65:438-447
pubmed: 30388518
Oxid Med Cell Longev. 2017;2017:6501046
pubmed: 28698768
Gut. 1976 Aug;17(8):571-5
pubmed: 976794
J Clin Med. 2019 Jun 04;8(6):
pubmed: 31167412
Nutrients. 2014 Apr 24;6(4):1752-81
pubmed: 24763117
Alcohol Alcohol. 2018 Jan 1;53(1):64-70
pubmed: 29136089
Antioxidants (Basel). 2020 Dec 03;9(12):
pubmed: 33287462
Int J Vitam Nutr Res. 1994;64(3):220-32
pubmed: 7814238
Eur J Clin Nutr. 2005 Oct;59(10):1181-90
pubmed: 16034362
Hepatology. 2006 Mar;43(3):485-91
pubmed: 16496307
Antioxidants (Basel). 2020 Nov 26;9(12):
pubmed: 33256059
Crit Rev Food Sci Nutr. 2021;61(5):742-755
pubmed: 32223303
Aliment Pharmacol Ther. 2005 Dec;22(11-12):1079-89
pubmed: 16305721

Auteurs

Virgile Clergue-Duval (V)

APHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Psychiatrie et de Médecine Addictologique, 75010 Paris, France.
Inserm UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, 75006 Paris, France.
FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.
UFR de Médecine, Université de Paris, 75006 Paris, France.
Resalcog (Réseau Pour la Prise en Charge des Troubles Cognitifs Liés à L'alcool), 75017 Paris, France.

Julien Azuar (J)

APHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Psychiatrie et de Médecine Addictologique, 75010 Paris, France.
Inserm UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, 75006 Paris, France.
FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.
Resalcog (Réseau Pour la Prise en Charge des Troubles Cognitifs Liés à L'alcool), 75017 Paris, France.

Julien Fonsart (J)

APHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Biochimie et Biologie Moléculaire, 75010 Paris, France.

Clément Delage (C)

Inserm UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, 75006 Paris, France.
APHP GHU Nord, Site Lariboisière Fernand-Widal, Service de Pharmacie, 75010 Paris, France.

Dorian Rollet (D)

APHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Psychiatrie et de Médecine Addictologique, 75010 Paris, France.
FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.

Jihed Amami (J)

APHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Psychiatrie et de Médecine Addictologique, 75010 Paris, France.
FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.

Alexia Frapsauce (A)

APHP GHU Nord, Site Lariboisière Fernand-Widal, Service de Pharmacie, 75010 Paris, France.

Marie-Astrid Gautron (MA)

FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.
APHP GHU Nord, Site Beaujon, Unité de Traitement Ambulatoire des Maladies Addictives, 92110 Clichy, France.

Eric Hispard (E)

APHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Psychiatrie et de Médecine Addictologique, 75010 Paris, France.
FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.

Frank Bellivier (F)

APHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Psychiatrie et de Médecine Addictologique, 75010 Paris, France.
Inserm UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, 75006 Paris, France.
FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.
UFR de Médecine, Université de Paris, 75006 Paris, France.

Vanessa Bloch (V)

Inserm UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, 75006 Paris, France.
FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.
APHP GHU Nord, Site Lariboisière Fernand-Widal, Service de Pharmacie, 75010 Paris, France.
UFR de Pharmacie, Université de Paris, 75006 Paris, France.

Jean-Louis Laplanche (JL)

Inserm UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, 75006 Paris, France.
APHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Biochimie et Biologie Moléculaire, 75010 Paris, France.
UFR de Pharmacie, Université de Paris, 75006 Paris, France.

Frank Questel (F)

APHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Psychiatrie et de Médecine Addictologique, 75010 Paris, France.
Inserm UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, 75006 Paris, France.
FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.
Resalcog (Réseau Pour la Prise en Charge des Troubles Cognitifs Liés à L'alcool), 75017 Paris, France.

Florence Vorspan (F)

APHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Psychiatrie et de Médecine Addictologique, 75010 Paris, France.
Inserm UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, 75006 Paris, France.
FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.
UFR de Médecine, Université de Paris, 75006 Paris, France.

Classifications MeSH